Last reviewed · How we verify
matching placebo of emodepside
At a glance
| Generic name | matching placebo of emodepside |
|---|---|
| Sponsor | Drugs for Neglected Diseases |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis (PHASE2)
- Emodepside Phase II Trial for Treatment of Onchocerciasis (PHASE2)
- Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- matching placebo of emodepside CI brief — competitive landscape report
- matching placebo of emodepside updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI